Summary segment financial performance measures
evaluated by the CODM as of December 31, 2025 and 2024 and for the years then ended is as follows:
Schedule of Segment Financial Performance
| | |
2025 | | |
2024 | |
| | |
Segment Assets at December 31, | |
| | |
2025 | | |
2024 | |
| Digital asset treasury segment | |
$ | 513,964,900 | | |
$ | - | |
| Clinical stage bio-technology segment | |
| 5,181,535 | | |
| 3,721,624 | |
| Total assets | |
$ | 519,146,435 | | |
$ | 3,721,624 | |
Digital asset treasury segment
| | |
2025 | | |
2024 | |
| | |
For the years ended December 31, | |
| | |
2025 | | |
2024 | |
| Loss from operations | |
$ | (2,765,292 | ) | |
$ | - | |
| Other income (expense) (a) | |
| 24,117 | | |
| - | |
| Unrealized loss on digital assets holdings | |
| (22,010,362 | ) | |
| - | |
Clinical stage bio-technology segment
| | |
2025 | | |
2024 | |
| | |
For the years ended December 31, | |
| | |
2025 | | |
2024 | |
| Loss from operations | |
$ | (17,340,774 | ) | |
$ | (12,433,792 | ) |
| Other income (expense) (a) | |
| (11,052 | ) | |
| 236,224 | |
| (a) | | Other income (expense) consists of interest income and interest expense. |
The
following table is a reconciliation of segment total loss before income taxes to our consolidated total loss before income taxes.
| | |
| | | |
| | |
| | |
For the years ended December 31, | |
| | |
2025 | | |
2024 | |
|